Alma Mater Cosméticos

Two doses per year could reshape HIV prevention, but price and licensing issues may limit scalability within the Brazilian public health system (SUS). The “quasi-vaccine” developed by Gilead Sciences arrives in Brazil with rare clinical evidence and global regulatory endorsement. But the geopolitics of voluntary licenses and the pricing logic in rich markets create a dilemma: how to remunerate innovation without turning prevention into a luxury incompatible with universality? On January 12,...

In early 2026, Novo Nordisk launched Wegovy in tablet form (oral semaglutide, daily use) in the US, with an announced entry price of US$149/month for initial doses, scaling to higher doses, and price adjustments expected from April 15th . This move helps to highlight a transition that goes beyond a simple product line extension: the global obesity market is becoming a game of leadership at scale , where "tablet versus injectable" is just the tip of the iceberg in a broader competition for...

How the global shift in health innovation redefines the role of industrial policies and exposes the backwardness of Brazil's strategy The pharmaceutical industry is experiencing a historic shift. The model that, for half a century, concentrated drug discovery in large, integrated corporations is fragmenting. Vertical integration, a symbol of strength in the 20th century, has given way to a decentralized network of small biotechs , academic laboratories, and deep tech startups that are...